On December 30, 2022, the Second China Biopharmaceutical Industry Chain Innovation and Transformation Summit Forum released the "2022 China Biopharmaceutical Industry Chain Innovation Billborads". R&G PharmaStudies Co., Ltd. (hereinafter referred to as "R&G") was honored with the 2022 Best Clinical CRO Enterprise Golden Horse Award in this selection.
The awards were presented at the opening ceremony of the "Nanjing International Summit on Innovation and Investment in Novel Medicine, Life Sciences & Health Care Industry" witnessed by academicians from China and abroad, leaders of relevant departments of national ministries and commissions, experts from university research institutes and clinical trial institutions, partners in the investment field, and executives of listed and pre-listing companies.
The jury for this edition of the ranking was composed of 9 outstanding experts from various fields of the biopharmaceutical industry, including government, industry, academia, research, finance, intermediaries, and medicine. The jury scored the participating enterprises based on product-level dimensions—innovation, status, layout, potential, competition—and enterprise-level dimensions—leadership, scale, stability, growth, strategy—combining standard scores, coefficients, and weights. Regarding this award, Mr. Wu Jie, Chairman and President of R&G, expressed gratitude to the pharmaceutical industry experts for their recognition and affirmation of R&G, and to all sectors of society for their attention and support. He stated that they will, as always, continue to make persistent efforts!
As a leading listed company in the CRO industry, R&G has always adhered to the mission of "for human health", upholding a customer-centric approach and embracing a service philosophy of "scientificity, professionalism and innovation". We provide global pharmaceutical companies with comprehensive, full-chain CRO services for clinical research. In various specialized fields, top domestic and international experts lead our company's "Innovative Drug Science and Strategy Committee", customizing research and development strategies and top-level designs for domestic and international pharmaceutical companies, optimizing clinical trial protocols, guiding new drug applications both in China and abroad, and achieving remarkable results.
Winning this award is a testament to the trust placed in the R&G brand by the pharmaceutical industry, industry experts, and our clients. In the new year, R&G will seize new development opportunities, leverage the company's own advantages, and assist our clients in their growth!
